Related Experiment Videos
Extracorporeal shock-wave lithotripsy in patients with spinal cord dysfunction
W L Niedrach1, R S Davis, F W Tonetti
1Department of Urology, University of Rochester School of Medicine, New York.
Urology
|August 1, 1991
Summary
Extracorporeal shock-wave lithotripsy (ESWL) effectively fragments kidney stones in patients with spinal cord dysfunction. However, stone clearance is delayed, with few patients achieving stone-free status within three months.
Area of Science:
- Urology
- Nephrology
- Spinal Cord Injury Medicine
Background:
- Patients with spinal cord dysfunction (SCD) face a higher incidence of urolithiasis.
- Managing kidney stones in this population presents unique challenges due to potential complications and altered physiology.
Purpose of the Study:
- To evaluate the efficacy and safety of extracorporeal shock-wave lithotripsy (ESWL) for treating urolithiasis in patients with spinal cord dysfunction.
- To assess stone fragmentation, clearance rates, and patient tolerance to ESWL in this specific cohort.
Main Methods:
- A retrospective study analyzing data from patients with spinal cord dysfunction who underwent ESWL.
- Review of treatment parameters, including the number of treatments, average shocks per renal unit, and stone fragmentation.
- Assessment of stone-free status at short-term (3 months) and long-term (5-15 months) follow-up.
Main Results:
- ESWL resulted in good fragmentation of stones in most treated kidneys (12 out of 13).
- None of the patients achieved stone-free status at the three-month follow-up.
- A significant proportion of patients (4 out of 9) with long-term follow-up became stone-free between five and fifteen months post-treatment.
- ESWL was generally well-tolerated by the patients.
Conclusions:
- While ESWL provides effective stone fragmentation in patients with spinal cord dysfunction, the stone clearance rate is poor and delayed.
- Further investigation and alternative or adjunctive treatment strategies may be necessary to improve stone-free outcomes in this patient group.